Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose paliperidone palmitate versus placebo in schizophrenia
2006-006434-17Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paliperidone palmitate in schizophrenia (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in PANSS total score from baseline to end of double-blind treatment. Started Nov 2016; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2006-006434-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006434-17.